Francesca Rocchetti Selected Research

S55746

1/2019	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
4/2018	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Francesca Rocchetti Research Topics

Disease

2	Neoplasms (Cancer) 04/2018 - 01/2016
1	Leukemia 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 04/2018
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 04/2018
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2016

Drug/Important Bio-Agent (IBA)

2	S55746IBA 01/2019 - 04/2018
1	S63845IBA 01/2019
1	venetoclaxIBA 04/2018
1	Apoptosis Regulatory ProteinsIBA 04/2018
1	Monoclonal AntibodiesIBA 01/2016
1	Peptides (Polypeptides)IBA 01/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2016

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2019
1	Therapeutics 01/2016